Gapping down
In reaction to disappointing earnings/guidance: MS -4.5% (missed on top and bottom lines; said volatility in global markets led to a difficult environment), VRX -2.3% (beats by $0.04, reports revs in-line; slightly raises Q4 guidance).
Other news: GNCA -32.2% (reports top-line results from a Phase 2a clinical trial for GEN-004, neither of the endpoints achieved statistical significance), GLDD -15.6% (initiates a review of potential strategic alternatives, withdraws FY15 EBITDA guidance, announces the retirement of CEO Jonathan W. Berger), SDRL -5.8% (commented on investigation into Sevan Marine/Drilling, prior to SDRL acquisition), PBR -3.7% (announces that its average production of oil and natural gas was 2.72 mln barrels of oil equivalent per day in September vs. 2.88 mln boed produced in August), ZINC -2.8% (general weakness in mining), FCX -2.4% (general weakness in mining), SUNE -2.2% (still checking for anything specific),SHPG -1.1% (receives a Complete Response Letter from the FDA regarding the NDA for lifitegrast for the signs and symptoms of dry eye disease in adults), AGN -0.9% (presents results of its HARMONY study).
Analyst comments: UBNT 3.3% (downgraded to Underperform at JMP Securities), ORCL -1.4% (downgraded to Sector Weight at Pacific Crest), TEF -1.3% (downgraded to Underperform from Neutral at Credit Suisse), STX -1.1% (downgraded to Neutral from Positive at Susquehanna).
Other news: GNCA -32.2% (reports top-line results from a Phase 2a clinical trial for GEN-004, neither of the endpoints achieved statistical significance), GLDD -15.6% (initiates a review of potential strategic alternatives, withdraws FY15 EBITDA guidance, announces the retirement of CEO Jonathan W. Berger), SDRL -5.8% (commented on investigation into Sevan Marine/Drilling, prior to SDRL acquisition), PBR -3.7% (announces that its average production of oil and natural gas was 2.72 mln barrels of oil equivalent per day in September vs. 2.88 mln boed produced in August), ZINC -2.8% (general weakness in mining), FCX -2.4% (general weakness in mining), SUNE -2.2% (still checking for anything specific),SHPG -1.1% (receives a Complete Response Letter from the FDA regarding the NDA for lifitegrast for the signs and symptoms of dry eye disease in adults), AGN -0.9% (presents results of its HARMONY study).
Analyst comments: UBNT 3.3% (downgraded to Underperform at JMP Securities), ORCL -1.4% (downgraded to Sector Weight at Pacific Crest), TEF -1.3% (downgraded to Underperform from Neutral at Credit Suisse), STX -1.1% (downgraded to Neutral from Positive at Susquehanna).